MicroRNA-216a is essential for cardiac angiogenesis.

Animals Mice Endothelial Cells / metabolism Neovascularization, Physiologic / genetics MicroRNAs / metabolism Heart Failure / metabolism Myocardium / metabolism Neovascularization, Pathologic / genetics
angiogenesis autophagy cardiac remodeling endothelial cells heart failure microRNAs

Journal

Molecular therapy : the journal of the American Society of Gene Therapy
ISSN: 1525-0024
Titre abrégé: Mol Ther
Pays: United States
ID NLM: 100890581

Informations de publication

Date de publication:
07 06 2023
Historique:
received: 06 02 2021
revised: 18 03 2023
accepted: 12 04 2023
pmc-release: 07 06 2024
medline: 12 6 2023
pubmed: 19 4 2023
entrez: 19 04 2023
Statut: ppublish

Résumé

While it is experimentally supported that impaired myocardial vascularization contributes to a mismatch between myocardial oxygen demand and supply, a mechanistic basis for disruption of coordinated tissue growth and angiogenesis in heart failure remains poorly understood. Silencing strategies that impair microRNA biogenesis have firmly implicated microRNAs in the regulation of angiogenesis, and individual microRNAs prove to be crucial in developmental or tumor angiogenesis. A high-throughput functional screening for the analysis of a whole-genome microRNA silencing library with regard to their phenotypic effect on endothelial cell proliferation as a key parameter, revealed several anti- and pro-proliferative microRNAs. Among those was miR-216a, a pro-angiogenic microRNA which is enriched in cardiac microvascular endothelial cells and reduced in expression under cardiac stress conditions. miR-216a null mice display dramatic cardiac phenotypes related to impaired myocardial vascularization and unbalanced autophagy and inflammation, supporting a model where microRNA regulation of microvascularization impacts the cardiac response to stress.

Identifiants

DOI: 10.1016/j.ymthe.2023.04.007 PMID: 37073128 PMC: PMC10277893
pubmed: 37073128
pii: S1525-0016(23)00205-8
doi: 10.1016/j.ymthe.2023.04.007
pmc: PMC10277893
pii:
doi:

Substances chimiques

MicroRNAs 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1807-1828

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests L.d.W. and P.d.C.M. are cofounders of Mirabilis Therapeutics.

Références

Nat Genet. 2000 Jun;25(2):139-40
pubmed: 10835623
Curr Biol. 2012 Jan 10;22(1):R29-34
pubmed: 22240478
Hypertension. 2006 May;47(5):887-93
pubmed: 16567591
Cell Death Differ. 2011 Apr;18(4):571-80
pubmed: 21311563
IEEE Trans Ultrason Ferroelectr Freq Control. 2013 May;60(5):888-97
pubmed: 23661123
Hepatology. 2013 Aug;58(2):629-41
pubmed: 23471579
Am J Physiol Heart Circ Physiol. 2019 Jan 1;316(1):H183-H185
pubmed: 30412440
Genes Dev. 2010 Jun 1;24(11):1173-85
pubmed: 20466812
N Engl J Med. 2013 May 9;368(19):1845-6
pubmed: 23656658
J Clin Invest. 2005 Aug;115(8):2108-18
pubmed: 16075055
J Mol Cell Cardiol. 2019 Feb;127:105-114
pubmed: 30553885
J Clin Invest. 2013 May;123(5):2143-54
pubmed: 23619365
Diabetes. 2012 Jun;61(6):1633-41
pubmed: 22427379
Cell. 2002 Sep 20;110(6):737-49
pubmed: 12297047
Heart. 2011 Feb;97(3):181-9
pubmed: 20884790
Biochem Biophys Res Commun. 1997 Aug 18;237(2):318-24
pubmed: 9268708
Cell Death Dis. 2014 Jan 30;5:e1029
pubmed: 24481443
Nat Cell Biol. 2010 Dec;12(12):1220-7
pubmed: 21102440
FEBS J. 2022 Jun;289(11):2976-2991
pubmed: 33934518
EMBO J. 2012 Nov 14;31(22):4304-17
pubmed: 23064152
Circulation. 2008 Oct 7;118(15):1567-76
pubmed: 18809798
Circ Res. 2004 Feb 20;94(3):e18-26
pubmed: 14739160
Am J Physiol Heart Circ Physiol. 2019 Jan 1;316(1):H106-H112
pubmed: 30412436
Circ Res. 2004 Jul 23;95(2):187-95
pubmed: 15192020
FASEB J. 2009 Oct;23(10):3335-46
pubmed: 19528256
Lancet. 2011 Jun 4;377(9781):1929-37
pubmed: 21621834
J Clin Invest. 2014 May;124(5):2136-46
pubmed: 24743145
Genes Dev. 2008 Dec 1;22(23):3242-54
pubmed: 19015276
Biosci Rep. 2020 Mar 27;40(3):
pubmed: 32124924
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Cell. 2008 Mar 7;132(5):875-86
pubmed: 18329372
Circ Res. 2007 Jul 6;101(1):59-68
pubmed: 17540974
Oncogene. 2015 Jun 11;34(24):3085-94
pubmed: 25132266
Nat Rev Cardiol. 2013 Sep;10(9):519-30
pubmed: 23856679
Circulation. 2003 Mar 18;107(10):1359-65
pubmed: 12642354
J Biol Chem. 2007 Mar 2;282(9):6763-72
pubmed: 17192262
Curr Opin Mol Ther. 2004 Apr;6(2):151-9
pubmed: 15195927
J Am Heart Assoc. 2014 Jan 21;3(1):e000285
pubmed: 24449802
J Drug Target. 2020 Jul;28(6):609-616
pubmed: 31791158
J Clin Invest. 2007 Nov;117(11):3188-97
pubmed: 17975666
EBioMedicine. 2020 Mar;53:102677
pubmed: 32114389
Heart Fail Rev. 2003 Jul;8(3):253-8
pubmed: 12878834
J Biol Chem. 2001 Sep 21;276(38):35786-93
pubmed: 11448956
Arterioscler Thromb Vasc Biol. 2012 Mar;32(3):545-7
pubmed: 22345589
Nat Cell Biol. 2012 Feb 12;14(3):249-56
pubmed: 22327366
Mol Cancer. 2020 Jan 22;19(1):12
pubmed: 31969156
Mol Ther. 2014 Sep;22(9):1665-77
pubmed: 24895996
Circ Res. 2015 Jun 19;117(1):52-64
pubmed: 25904597
J Cell Mol Med. 2018 May;22(5):2739-2749
pubmed: 29512862
J Biomed Opt. 2012 May;17(5):056016
pubmed: 22612139
Cardiovasc Res. 2009 May 1;82(2):250-60
pubmed: 19147653
Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20364-71
pubmed: 24277826
Development. 2008 Dec;135(24):3989-93
pubmed: 18987025
Biomed Res Int. 2015;2015:592512
pubmed: 25710008
J Biol Chem. 2000 May 5;275(18):13571-9
pubmed: 10788473
Biochim Biophys Acta Mol Basis Dis. 2019 Jul 1;1865(7):1772-1781
pubmed: 29940270
Expert Opin Biol Ther. 2003 Jul;3(4):599-616
pubmed: 12831365
Arterioscler Thromb Vasc Biol. 2011 Dec;31(12):2787-91
pubmed: 22096098
J Clin Invest. 2015 Jan;125(1):55-64
pubmed: 25654551
J Biol Chem. 2008 Aug 8;283(32):22295-303
pubmed: 18477567
J Mol Cell Cardiol. 2014 Sep;74:139-50
pubmed: 24825548
RNA. 2015 Apr;21(4):675-7
pubmed: 25780186
J Biomed Opt. 2011 Jul;16(7):076003
pubmed: 21806264
Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2111-6
pubmed: 18256189
Clin Cancer Res. 2014 Sep 1;20(17):4705-16
pubmed: 24958806
Circulation. 2006 Jul 25;114(4):298-308
pubmed: 16847152
Cell Physiol Biochem. 2018;47(5):2067-2076
pubmed: 29975938
Nat Rev Cardiol. 2009 Aug;6(8):515-23
pubmed: 19528962
Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2415-20
pubmed: 18272492
Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14082-7
pubmed: 18779589
Proc Natl Acad Sci U S A. 1991 Sep 15;88(18):8277-81
pubmed: 1832775
Theranostics. 2014 Mar 18;4(6):604-13
pubmed: 24723982
Nat Cell Biol. 2013 Nov;15(11):1282-93
pubmed: 24161931
Proc Natl Acad Sci U S A. 2014 Jul 15;111(28):E2851-7
pubmed: 24982181
Genes Dev. 2016 Feb 15;30(4):399-407
pubmed: 26883359
Nat Genet. 2006 Jun;38 Suppl:S14-9
pubmed: 16736018
Biochim Biophys Acta. 2015 Feb;1852(2):290-8
pubmed: 25229693
Am J Physiol Cell Physiol. 2010 Dec;299(6):C1256-66
pubmed: 20861467
PLoS One. 2013 May 07;8(5):e63074
pubmed: 23667577
Genome Biol. 2006;7(10):R100
pubmed: 17076895

Auteurs

Rio P Juni (RP)

CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, 6229 ER Maastricht, the Netherlands; Department of Physiology, Amsterdam University Medical Centers, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.

Jordy M M Kocken (JMM)

CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, 6229 ER Maastricht, the Netherlands.

Ricardo C Abreu (RC)

CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, 6229 ER Maastricht, the Netherlands; Biomaterials and Stem Cell Based Therapeutics Group, CNC-Center for Neuroscience and Cell Biology, CIBB-Centre for Innovative Biomedicine and Biotechnology, University of Coimbra, UC, Biotech Parque Tecnológico de Cantanhede, 3060-197 Coimbra, Portugal.

Lara Ottaviani (L)

CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, 6229 ER Maastricht, the Netherlands.

Tim Davalan (T)

CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, 6229 ER Maastricht, the Netherlands.

Burcu Duygu (B)

CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, 6229 ER Maastricht, the Netherlands.

Ella M Poels (EM)

CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, 6229 ER Maastricht, the Netherlands.

Aliaksei Vasilevich (A)

Department of Biomedical Engineering and Institute for Complex Molecular Systems, University of Eindhoven, Eindhoven, the Netherlands.

Jana C Hegenbarth (JC)

CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, 6229 ER Maastricht, the Netherlands.

Mahesh Appari (M)

Division of Cardiovascular Medicine, British Heart Foundation Centre of Research Excellence, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 9DU United Kingdom.

Nicole Bitsch (N)

CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, 6229 ER Maastricht, the Netherlands.

Serve Olieslagers (S)

CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, 6229 ER Maastricht, the Netherlands.

Dorien M Schrijvers (DM)

Laboratory of Physiopharmacology, University of Antwerp, 2610 Wilrijk, Belgium.

Monika Stoll (M)

Department of Genetic Epidemiology, Institute of Human Genetics, University of Münster, 48149 Münster, Germany; Department of Biochemistry, CARIM School for Cardiovascular Diseases, Maastricht University, 6229 ER Maastricht, the Netherlands.

Joerg Heineke (J)

Department of Cardiovascular Physiology, European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany; DZHK, Partner Site Heidelberg/Mannheim, 69120 Heidelberg, Germany.

Jan de Boer (J)

Department of Biomedical Engineering and Institute for Complex Molecular Systems, University of Eindhoven, Eindhoven, the Netherlands.

Leon J de Windt (LJ)

CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, 6229 ER Maastricht, the Netherlands.

Paula A da Costa Martins (PA)

CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, 6229 ER Maastricht, the Netherlands; Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, 4200-319 Porto, Portugal. Electronic address: p.dacostamartins@maastrichtuniversity.nl.

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Use of organic material provided by an automatic enrichment device by weaner pigs and its influence on tail lesions.

Philipp Heseker, Jeanette Probst, Stefanie Ammer et al.
1.00
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › MicroRNA-216a is essential for cardiac angiogenesis.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › MicroRNA-216a is essential for cardiac angiogenesis.
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules endothéliales › MicroRNA-216a is essential for cardiac angiogenesis.
questionsmedicales.fr › Phénomènes physiologiques respiratoires et circulatoires › Phénomènes physiologiques cardiovasculaires › Néovascularisation physiologique › MicroRNA-216a is essential for cardiac angiogenesis.
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › ARN non traduit › Petit ARN non traduit › microARN › MicroRNA-216a is essential for cardiac angiogenesis.
questionsmedicales.fr › Maladies cardiovasculaires › Cardiopathies › Défaillance cardiaque › MicroRNA-216a is essential for cardiac angiogenesis.
questionsmedicales.fr › Tissus › Muscles › Muscle strié › Myocarde › MicroRNA-216a is essential for cardiac angiogenesis.
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Métaplasie › Néovascularisation pathologique › MicroRNA-216a is essential for cardiac angiogenesis.